A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the study drug, suvorexant, is safe and effective in
treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a
total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of
insomnia will participate in the study at this site